Monday, October 22, 2007

10:00 AM-8:00 PM  Registration
                   First Floor Lobby

1:30 PM-3:30 PM  Educational Session 1:
                   Predictive Biomarkers and
                   Functional Imaging as Aids to
                   Drug Development
                   Room 2014

Chairperson: Julius Leyton, Imperial College, London, England

PET Tracers as Biomarkers in Oncology
Drug Development*
Julius Leyton, Imperial College, London, England

Pharmacogenomic Applications in Oncology
Drug Development
Nicholas C. Dracopoli, Bristol-Myers Squibb Company, Princeton, NJ, USA

Functional Imaging as Aids to Drug Development
Patricia M. Price, Christie Hospital NHS Trust, Manchester, England

6:00 PM-7:30 PM  Opening Reception
                   San Francisco Marriott
                   Yerba Buena Ballroom, Salon 7/8

Tuesday, October 23, 2007

7:00 AM-8:00 AM  Continental Breakfast
                   Third Floor Lobby

8:00 AM-8:05 AM  Opening Remarks
                   Third Floor Ballroom

Sara A. Courtneidge, James H. Doroshow, and Alexander M. M. Eggermont, Scientific Committee Chairpersons

8:05 AM-10:05 AM  Keynote Addresses
                   Third Floor Ballroom

Molecular Profiling and Breast Cancer: Towards Better Risk Estimation, Prognostication, and Prediction*
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway

Discovery of Disease Alleles and Drug Targets in Myeloid Leukemias
Dwight Gary Gilliland, Harvard Medical School, Boston, MA, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
10:05 AM-10:30 PM  Coffee Break  
Third Floor Lobby

10:30 AM-12:30 PM  Plenary Session 1:  
Cancer Stem Cells  
Third Floor Ballroom

Chairperson: Peter B. Dirks, Hospital for Sick Children, Toronto, ON, Canada

Brain Tumor Stem Cells: Chemical Determinants of Self Renewal  
*Peter B. Dirks*, Hospital for Sick Children, Toronto, ON, Canada

Examining the Role of Stem Cell Biology in Lung Cancer*  
*Carla Kim*, Children's Hospital, Boston, MA, USA

Characterization and Targeting of Human Leukemia Stem Cells*  
*Craig T. Jordan*, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, USA

Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma*  
*Laurie Ailles*, Stanford University School of Medicine, Palo Alto, CA, USA

4:30 PM-5:30 PM  Plenary Session 2:  
Targeting DNA Repair Pathways  
Third Floor Ballroom

Chairperson: Alan Ashworth, Institute of Cancer Research, London, England

DNA Damage-Activated Kinases as Targets for Cancer Therapy*  
*Roger J. Griffin*, Newcastle University, Newcastle upon Tyne, England

Targeting Fanconi Anemia/BRCA Pathway Defects in Cancer Therapeutics*  
*Alan D. D'Andrea*, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

5:30 PM-7:30 PM  Poster Session A/Exhibits (continued)  
First Floor Exhibit Hall

12:30 PM-2:30 PM  Poster Session A/Exhibits  
First Floor Exhibit Hall

2:30 PM-4:30 PM  Plenary Session 2: Targeting DNA Repair Pathways  
Third Floor Ballroom

Chairperson: Alan Ashworth, Institute of Cancer Research, London, England

Right Silencing and Stratified Therapy in Glioblastoma*  
*Monika E. Hegi*, University Hospital, Lausanne, Switzerland

ERCC1 as Relevant Targets in the DNA Repair Pathway*  
*Jean-Charles Soria*, Institut Gustave-Roussy, Villejuif, France

PR-1 Inhibition of IGF-1R by OSI-906 Potentiates Efficacy of Various Molecular Targeted Agents by Blocking Feedback Loops Converging at the Level of IRS-1*  
*Elizabeth Buck*, OSI Pharmaceuticals, Inc., Farmingdale, NY, USA

PR-2 Design, Synthesis, and Evaluation of Bivalent Conformationally Constrained Smac Mimetics that Concurrently Target both BIR2 and BIR3 Domain of XIAP*  
*Haiying Sun*, University of Michigan, Ann Arbor, MI, USA

PR-3 RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Traditional Cytotoxic Agents in Breast Cancer Cells*  
*Scott E. Martin*, National Cancer Institute, Bethesda, MD, USA

PR-4 Breast Cancer Cells Resistant to Anti-hormone Treatments Retain Sensitivity to Aminoflavone (NSC 686288)*  
*Phillip Shelton*, University of Maryland, School of Medicine, Baltimore, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**Wednesday, October 24, 2007**

**7:00 AM-8:00 AM**  
**Continental Breakfast**  
Third Floor Lobby

**8:00 AM-10:00 AM**  
**Plenary Session 3:**  
**Epigenetic Targets**  
Third Floor Ballroom  
**Chairperson: Kristian Helin, University of Copenhagen, Copenhagen, Denmark**

- Epigenetic Control and the Development of Cancer*  
  **Kristian Helin, University of Copenhagen, Copenhagen, Denmark**

- Title to Be Announced  
  **Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, USA**

- The Cancer Epigenome*  
  **Peter A. Jones, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA**

- Chromatin Alterations in Leukemias*  
  **Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy**

**10:00 AM-10:30 AM**  
**Coffee Break**  
Third Floor Lobby

**10:30 AM-12:30 PM**  
**Plenary Session 4:**  
**Genome-wide Approaches to Diagnosis, Stratification, and Target Identification**  
Third Floor Ballroom  
**Chairperson: Louis M. Staudt, National Cancer Institute, Bethesda, MD, USA**

- Predicting Effectiveness and Understanding Resistance to Targeted Inhibitors: Lessons from EGFR in Lung Cancer  
  **Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA**

- Cancer Genetic Markers of Susceptibility: Genome-wide Association Studies in Breast and Prostate Cancer  
  **Stephen Chanock, National Cancer Institute, Bethesda, MD, USA**

- Mechanisms of Resistance to NOTCH1 Inhibitors in T-ALL  
  **Adolfo Ferrando, Columbia University Medical Center, New York, NY, USA**

- From Genomic Diversity to Tumor Dependency in Human Cancer*  
  **Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA**

**12:30 PM-2:30 PM**  
**Poster Session B/Exhibits**  
First Floor Exhibit Hall

**2:30 PM-4:30 PM**  
**Concurrent Session 1:**  
**High Throughput Screens for Target Identification**  
Room 2001  
**Chairperson: René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands**

- Biomarkers of Resistance to Cancer Therapy Discovered through Functional Genetic Screens*  
  **René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands**

- Functional Genomics of Chemosensitivity Exposes Deviant Cancer Cell Regulatory Systems  
  **Michael A. White, University of Texas Southwestern Medical Center, Dallas, TX, USA**

- Achilles Heel RNA Interference Screens for Molecular Targets in Cancer*  
  **Louis M. Staudt, National Cancer Institute, Bethesda, MD, USA**

- Using Cellular Pharmacogenomics to Identify and Prioritize Genetic Determinants of Drug Response  
  **Jeffrey M. Trent, TGen, Phoenix, AZ, USA**

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings.*
2:30 PM - 4:30 PM Concurrent Session 2: Small Molecule Approaches to the Regulation of Apoptosis
Room 2007

Chairperson: Louis J. Lombardo, Bristol-Myers Squibb Company, Princeton, NJ, USA

Design of Small-molecule SMAC Mimetics as Apoptosis Inducers in Tumor Cells: Molecular Insights into Apoptosis Regulation
Shaomeng Wang, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

Drugging “Undruggable” Targets*
Gregory L. Verdine, Harvard University, Cambridge, MA, USA

Structure-based Design of IAP Antagonists*
Wayne J. Fairbrother, Genentech, Inc., South San Francisco, CA, USA

Apoptosis Based Therapies from a Medicinal Chemistry Perspective*
Maurizio Pellecchia, Burnham Institute for Medical Research, La Jolla, CA, USA

2:30 PM - 4:30 PM Concurrent Session 3: Tumor Microenvironment and Metastasis
Room 2014

Chairperson: Valerie M. Weaver, University of California, San Francisco, CA, USA

Spatial-Mechanical Cues from the Microenvironment Modulate Malignant Transformation and Treatment Efficacy
Valerie M. Weaver, University of California, San Francisco, CA, USA

Molecular Mechanisms Promoting Tumor Metastasis to Lymph Nodes and Beyond*
Judith A. Varner, University of California, San Diego Cancer Center, La Jolla, CA, USA

Cancer Therapeutic Agents Act Directly on Targets in the Microenvironment
Michael B. Sporn, Dartmouth Medical School, Hanover, NH, USA

Lymphatic Metastasis: How Tumor Cells Find the Best Escape Route
Melody Swartz, École Polytechnique Federale de Lausanne, Lausanne, Switzerland

2:30 PM - 4:30 PM Concurrent Session 4: Emerging Kinase Targets
Room 2020

Chairperson: Judith S. Sebolt-Leopold, JS Leopold Consulting, Ann Arbor, MI, USA

Genetic Predictors of MAP Kinase Dependence
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Targeting the IGF Receptor as Treatment for Cancer*
V. M. Macaulay, Weatherall Institute of Molecular Medicine, Oxford, England

Exploiting the Kinome to Target Signaling and Cell Cycle Regulation*
Michelle D. Garrett, Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, Sutton, England

Cell Growth Control by mTORC1 and S6K Signaling
John Blenis, Harvard Medical School, Boston, MA, USA

4:30 PM - 5:30 PM Proffered Paper Session 2
Third Floor Ballroom

PR-5 Inhibition of CDK2 is a New Potential Therapy for Childhood Neuroblastoma Over-expressing N-Myc*
Jan J. Molenaar, University of Amsterdam, Amsterdam, The Netherlands

PR-6 A Phase I Trial of the Heat Shock Protein 90 (HSP90) Inhibitor Alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) Administered Weekly, Intravenously, to Patients with Advanced, Solid Tumors*
Simon C. Pacey, The Institute of Cancer Research, Sutton, England

PR-7 Efficacy, Safety, and Changes in Angiogenic Markers Following Sunitinib Monotherapy in Patients with Advanced Hepatocellular Carcinoma: Experience from a Phase II Study*
Andrew X. Zhu, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

PR-8 Nerve-sparing Therapy with Oncolytic Herpes Virus for Cancers with Neural Invasion*
Ziv A. Gil, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**5:30 PM - 7:30 PM** Poster Session B/Exhibits (continued)
First Floor Exhibit Hall

**Thursday, October 25, 2007**

**7:00 AM - 8:00 AM** Continental Breakfast
Third Floor Lobby

**8:00 AM - 10:00 AM** Plenary Session 5: Tumor Immunology
Third Floor Ballroom

*Chairperson: James P. Allison,* Memorial Sloan-Kettering Cancer Center, New York, NY, USA

- Immune Checkpoint Blockade in Cancer Therapy
  *James P. Allison,* Memorial Sloan-Kettering Cancer Center, New York, NY, USA

- Regulating Regulatory T Cells: A Novel Strategy to Augment Anti-tumor Immunity
  *Bernard A. Fox,* R. W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA

- Failure at the Effector Phase: Immune Resistance in the Tumor Microenvironment*
  *Thomas F. Gajewski,* University of Chicago, Chicago, IL, USA

- Immunogenicity of Cytotoxic Drugs: Molecular Bases and Clinical Implementation*
  *Laurence Zitvogel,* Institut Gustave-Roussy, Villejuif, France

**10:00 AM - 10:30 AM** Coffee Break
Third Floor Lobby

**10:30 AM - 12:30 PM** Plenary Session 6: Towards Personalized Cancer Therapy
Third Floor Ballroom

*Chairperson: Tona M. Gilmer,* GlaxoSmithKline, Research Triangle Park, NC, USA

- Molecular Diagnostics: A Need to Improve Cancer Care
  *Laura J. van’t Veer,* The Netherlands Cancer Institute, Amsterdam, The Netherlands

- Integrated Genomic Test to Aid Treatment Selection
  *Lajos Pusztai,* University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

- Optimizing Therapy through Pharmacogenomics
  *Kathleen D. Danenberg,* Response Genetics, Inc., Los Angeles, CA, USA

- HER2/neu: A Practical Example
  *Clifford A. Hudis,* Memorial Sloan-Kettering Cancer Center, New York, NY, USA

*Panel Discussion*

**12:30 PM - 2:30 PM** Poster Session C/Exhibits
First Floor Exhibit Hall

**2:30 PM - 4:30 PM** Concurrent Session 5: Cancer Cell Metabolism
Room 2001

*Chairperson: Craig B. Thompson,* University of Pennsylvania, Philadelphia, PA, USA

- Therapeutic Targeting of Cancer Cell Metabolism
  *Craig B. Thompson,* University of Pennsylvania, Philadelphia, PA, USA

- Cancer Cell Metabolism in the Crosshairs: Targeting the mTOR Pathway for Cancer Therapy*
  *Robert T. Abraham,* Wyeth Pharmaceuticals, Pearl River, NY, USA

- Role of the M2 Splice Isoform of Pyruvate Kinase in Tumor Cell Metabolism and Proliferation
  *Heather Christofk,* Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

- Targeting Survivin in Cancer Therapy: Fulfilled Promises and Open Questions*
  *Nadia Zaffaroni,* Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.*
2:30 PM - 4:30 PM Concurrent Session 6: Rational Drug Combinations
Room 2007

**Chairperson: Roman Perez-Soler**, Montefiore Medical Center, Bronx, NY, USA

Synergistic Schedules with Combinations of EGFR Inhibitors and Cytotoxic Agents*

**Roman Perez-Soler**, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Epigenetic Therapies: What is the Target?

**Steven D. Gore**, Johns Hopkins University, Baltimore, MD, USA

Combinations with Angiogenesis Inhibitors

**John V. Heymach**, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Multi-targeted Suppression of the RAS-AKT Signaling Network in NSCLC*

**Hayley M. McDaid**, Albert Einstein College of Medicine, Bronx, NY, USA

---

2:30 PM - 4:30 PM Concurrent Session 7: Protein Stability and Turnover
Room 2014

**Chairperson: Neal Rosen**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Hsp90-dependent Protein Folding as a Therapeutic Target in Cancer

**Neal Rosen**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer*

**Mark Rolfe**, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA

Regulation of hsp90 Chaperone Activity by Acetylation*

**Leonard M. Neckers**, National Cancer Institute, Bethesda, MD, USA

Exploiting Molecular Chaperone Addiction in Cancer: New Drugs and Biomarkers

**Paul Workman**, Cancer Research UK Centre for Cancer Therapeutics, Sutton, Surrey, England

---

2:30 PM - 4:30 PM Concurrent Session 8: Re-Engineering Tumor Suppression
Room 2020

**Chairperson: Karen H. Vousden**, Beatson Institute for Cancer Research, Glasgow, Scotland

The p53 Tumor Suppressor as a Therapeutic Target

**Karen H. Vousden**, Beatson Institute for Cancer Research, Glasgow, Scotland

Overcoming the Loss of Mitochondrial Tumor Suppressors by Reactivating HIF Prolyl Hydroxylases*

**Eyal Gottlieb**, Cancer Research UK Beatson Laboratories, Glasgow, Scotland

Targeting Bcl-2 Family Proteins to Treat Cancer*

**Steven W. Elmore**, Abbott Laboratories, Abbott Park, IL, USA

Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects*

**Alan Ashworth**, Institute of Cancer Research, London, England

---

4:30 PM - 5:30 PM Proffered Paper Session 3
Third Floor Ballroom

**PR-9** Study of Tumor Perfusion Parameters Obtained Using Dynamic Contrast Enhanced Ultrasonography (DCE-US) in a Phase I Trial of Patients Treated with Sorafenib and Dacarbazine*

**Nathalie Lassau**, Institut Gustave Roussy, Villejuif, France

**PR-10** MET Amplification Occurs with or without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib*

**James Bean**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

**PR-11** Inhibition of Colon Tumor Metastasis in Orthotopic Nude Mouse Models with the Dual-selective Src/Abi Kinase Inhibitor, AZD0530*

**K. A. Phillips**, Departments of Surgical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

**PR-12** AR47A6.4.2, a Functional Naked Monoclonal Antibody Targeting Trop-2, demonstrates in vivo Efficacy in Human Pancreatic, Colon, Breast and Prostate Cancer Models*

**Amandine H. L. Truong**, Arius Research Inc., Toronto, ON, Canada

---

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.*
Friday, October 26, 2007

7:00 AM-8:00 AM  Continental Breakfast
Third Floor Lobby

8:00 AM-10:00 AM  Plenary Session 7:
Therapeutic Potential of Developmental Genes
Third Floor Ballroom

Chairperson: Jon C. Aster, Brigham and Women’s Hospital, Boston, MA, USA

Targeting Notch in Cancer: Challenges and Opportunities
Jon C. Aster, Brigham and Women’s Hospital, Boston, MA, USA

Novel Molecular Targets in Breast Cancer Progression
Lewis A. Chodosh, University of Pennsylvania, Philadelphia, PA, USA

Notch 1 Inhibitors in Mouse T-ALL Models
Michelle A. Kelliher, University of Massachusetts Medical School, Worcester, MA, USA

Notch Antibody Antagonists for Cancer Therapy*
Christian W. Siebel, Genentech, Inc., South San Francisco, CA, USA

10:00 AM-10:30 AM  Coffee Break
Third Floor Lobby

10:30 AM-12:30 PM  Plenary Session 8:
New Clinical Trial Design
Third Floor Ballroom

Chairperson: James H. Doroshow, National Cancer Institute, Bethesda, MD, USA

Potential Utilities of the Study of Circulating Tumor Cells in the Design of Clinical Trials of Molecularly Targeted Drugs*
Johann S. de Bono, Royal Marsden Hospital, Sutton, England

New Concepts in Phase II Design
Mark J. Ratain, University of Chicago, Chicago, IL, USA

Clinical Trial Designs for Early Drug Development
James A. Zwiebel, National Cancer Institute, Rockville, MD, USA

Title to Be Announced

Panel Discussion

12:30 PM-12:45 PM  Closing Ceremony
Third Floor Ballroom

Sara A. Courtneidge, Scientific Committee Chairperson

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.